Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
Wan-Ling TanQuan Sing NgCindy LimEng Huat TanChee Keong TohMei-Kim AngRavindran KanesvaranAmit JainDaniel S W TanDarren Wan-Teck LimPublished in: BMC cancer (2018)
In patients with advanced EGFRm+ NSCLC with BM+, initiating patients on afatinib 40 mg OD was associated with improved PFS compared to 30 mg OD, underscoring the potential importance of dose intensity in control of CNS disease.